Further studies are needed to determine whether SPEN mutations as well as other NOTCH1 regulatory pathway mutations are associated with increased transformation risk or poor response to frontline chemo-immunotherapy or targeted agents currently used for CLL patients. The gene discussed is NOTCH1; the disease is B-cell chronic lymphocytic leukemia.